Search

Abstract: In this study we report the synthesis and activity against bovine viral diarrhea virus (BVDV) of a novel series of bicycle δ-sultones containing γ-lactones. BVDV is responsible for major losses in cattle. Some of the synthesized δ-sultones showed pronounced anti-BVDV activity with EC50 values of 0.12–1.0μM and no significant cytotoxicity. Among them, the ortho bromosubstituted derivative 4f (EC50 =0.12μM) showed better antiviral activity than other derivatives and was 10 fold more that of than positive control ribavirin (EC50 =1.3μM). BVDV is also considered to be a valuable surrogate for the hepatitis C virus (HCV) in antiviral drug studies. The above results provided a novel candidate for the development of anti-HCV agents. [Copyright &y& Elsevier]

Background & Aims: Detection of hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells (PBMC) and/or hepatocytes in absence of HCV RNA in serum, designated as ‘occult HCV infection’, has been a matter of controversy in recent years. We investigated for the first time the prevalence of occult HCV infection in large cohorts of chronic hemodialysis (CHD) and kidney transplant (KTx) patients. Methods: We enrolled 417 CHD patients, 417 KTx recipients and 2 control groups – 25 anti-HCV (antibody against HCV)-positive and HCV RNA-positive patients with chronic hepatitis C, and 40 anti-HCV-, HCV RNA-, and HBsAg-negative healthy subjects. HCV RNA was tested in serum and PBMC using a sensitive commercial assay. Results: In CHD patients, the prevalence of anti-HCV was 3.6% (15/417) and of positive serum HCV RNA 2.4% (10/417). HCV RNA was detected in PBMC in 1/407 (0.25%) HCV serum RNA-negative patients (“occult HCV infection”). In KTx recipients, prevalence of anti-HCV was 4.8% (20/417) and of positive serum HCV RNA 4.6% (19/417). Occult HCV infection was found in 2/398 (0.5%) serum HCV RNA-negative patients. On a mean longitudinal follow-up of 30months of the 3 patients with occult HCV infection, there was no clinical or virological evidence of HCV infection. Conclusions: The prevalence of occult HCV infection was very low in our CHD and KTx patients, and it did not appear to be clinically relevant. Further studies in geographic populations with high HCV endemicity are required to clarify the significance of occult HCV infection in these patient groups. [Copyright &y& Elsevier]

Background: Anti HCV is transferred from positive mother to her newborn. To prevent this transfer of anti HCV, many health care providers stop the mother from breast feeding and recommend the checking of the newborn for anti HCV. If found positive, they take it as a chronic infection and recommend treatment of the child as soon as possible. Prohibition from breast feeding not only pushes these neonates towards nutritional deficiencies but also make them prone to infections. The testing also stigmatizes the mother and her newborn for life. The literature proves that this antibody transfer is passive and clears in majority of cases without any residual disease. Mother to infant transfer of anti-HCV and its natural course in Pakistani population is not known. Objectives: To determine the frequency of anti-HCV positivity and its natural course in infants born to anti-HCV reactive mothers. Subjects and Methods: Anti-HCV reactive mothers were registered from gynecology department and labor room of Nishtar Hospital Multan from 07-10-2010 to 07-04-2011, using non probability purposive sampling. The ALT of mothers was also checked. The babies born to these mothers were checked for anti- HCV by ELISA and ALT at 0 day (at the time of birth) and then at 6, 12, 18 and 24 months using venous blood samples. Data was entered and analyzed using SPSS-11. Results: Out of 35 anti-HCV reactive mothers; only one had ALT above the upper limit of normal (> 40 IU/L). A total of 35 babies were born to these mothers, out of whom 34(97.1%) were reactive to anti-HCV at the time of birth and only one was non reactive. At 6 months 2 babies had expired and 3 were lost to follow up, leaving 30 babies. Out of these 30 babies 11 became non-reactive and 19 were still reactive for anti-HCV at 6months. At 12 months, all 19 anti-HCV reactive cases became non reactive, indicating passive transfer of antibodies from the mother to these neonates which they lost by 12 months. ALT of all babies except 3 was raised at 6 months (> 40 IU/L) which became normal during the subsequent visits. Conclusion: Almost all children born to anti-HCV positive mothers were reactive at the time of delivery but they all became non-reactive by the age of 12 months indicating passive transfer of anti HCV from the mother to the neonate. [ABSTRACT FROM AUTHOR]

Background: Hepatitis C virus (HCV) is transmitted by blood and blood products and it causes a major proportion of transfusion transmitted hepatitis. It can lead to chronic liver disease which has great morbidity and mortality. HCV is responsible for more deaths than Human immunodeficiency virus (HIV). As no vaccine is available and as the treatment is costly and lengthy, with a poor success rate, donor screening remains a very important means of primary prevention of HCV transmission. Aims and Objectives: This study was conducted to know the prevalence of anti-HCV in healthy voluntary blood donors (VBD) in a semi-urban region of western Maharashtra, India with a special focus on female donors. Settings and Design: This was an unlinked, anonymous, retrospective study. Materials and Methods: During January 2006 to December 2012, sera of 17976 VBD, which comprised of 16972 (94.41%) males and 1004 (5.59%) females, were tested for presence of anti-HCV antibody (anti-HCV) by using a 3rd generation ELISA test. Data was statistically analyzed by using Chi-Square for linear trends (Extended Mantel-Haenszel test). - 0.72732. Results and Conclusion: Thirty six donors (0.2%) were positive for anti-HCV. Seroprevalence in males was 0.21%, while that in females was 0%. The positivity of anti-HCV remained stable over the tenure of this study (Chi-Square for linear trends - 0.72732). This region has a lower prevalence of anti-HCV as compared those seen in other states of India. Zero prevalence in women indicated that encouraging women to undergo blood donations would still reduce the transmission of HCV. Detection can be improved by doing better tests like HCV RNA detection and further prevention of HCV transmission can be enhanced. [ABSTRACT FROM AUTHOR]

Hepatitis C virus (HCV) is a major cause of liver disease worldwide. The routine diagnostics identifying HCV infection include testing for specific anti-HCV antibodies by enzyme-linked immnunosorbent assay and viral genetic material in serum or plasma. However, a small proportion of patients persistently infected with HCV, in whom anti-HCV are undetectable, constitute a serious diagnostic and possibly epidemiologic problem, as they could facilitate pathogen spread in the population. This type of infection is termed seronegative or serosilent. Seronegative HCV infection is currently of great interest to both scientists and physicians. The review presents epidemiological data concerning the prevalence of seronegative HCV infection in HIV/HCV co-infected individuals, hemodialysis patients, and blood and organ donors. The possible mechanisms behind this atypical course of infection are discussed. Furthermore, the differences between seronegative and occult infections and prolonged seroconversion are explained. [ABSTRACT FROM AUTHOR]

The prevalence of hepatitis B and C infection has been determined in a seroepidemiological survey among blood donors from the south of Brazil (Florianópolis, State of Santa Catarina). These markers has also been correlated with the levels of alanine aminotransferase (ALT), a surrogate marker to prevent post-transfusion hepatitis. Sera from 5000 donors were randomly collected in the period of April to November 1991. The prevalences of HBsAg, anti-HBs and anti-HBc were respectively 0.78, 7.02 and 13.98. The anti-HCV prevalence after confirmation testing with line immunoassay (LIA), was 1.14. Normal values of ALT ( < = 32 U/ml) were found in 59.78, values slightly above the mean (ALT between 32-70 U/ml) in 37.74 and high values of ALT ( > = 70 U/ml) in 2.48. The positivity of anti-HCV antibodies increased with the elevation of ALT levels. This correlation was not observed in relation to HBsAg. There exists a diversity in the recognition of HCV epitopes among HCV positive donors. Via the confirmation test used, we could observe that 94.7 of donors recognize the structural core antigen. Besides that, we observed that 5.26 of the HCV reactive sera recognized only epitopes located in the NS4 and/or NS5 region, indicating the importance of these epitopes for the improvement of assays.

Data concerning HCV infection in Central Brazil are rare. Upon testing 2,350 voluntary blood donors from this region, we found anti-HCV prevalence rates of 2.2% by a second generation ELISA and 1.4% after confirmation by a line immunoassay. Antibodies against core, NS4, and NS5 antigens of HCV were detected in 81.8%, 72.7%, and 57.5%, respectively, of the positive samples in the line immunoassay. HCV viremia was present in 76.6% of the anti-HCV-positive blood donors. A relation was observed between PCR positivity and serum reactivity in recognizing different HCV antigens in the line immunoassay. The majority of the positive donors had history of previous parenteral exposure. While the combination of ALT>50 IU/l and anti-HBc positivity do not appear to be good surrogate markers for HCV infection, the use of both ALT anti-HCV tests is indicated in the screening of Brazilian blood donors.Ainda são raros os dados sobre a infecção pelo vírus da hepatite C (HCV) na região central do Brasil. Neste estudo, 2.350 doadores voluntários de sangue foram avaliados, resultando em prevalências para o anti-HCV de 2,2%, pelo ELISA de segunda geração, e de 1,4%, após o ensaio confirmatório "line immunoassay". Anticorpos contra os antígenos "core", NS4 e NS5 do HCV foram detectados em 81,8%, 72,7% e 57,5% das amostras positivas no "line immunoassay", respectivamente. A viremia do HCV foi observada em 76,6% dos doadores anti-HCV positivos. A positividade na reação em cadeia da polimerase (PCR) mostrou-se relacionada a reatividade aos diferentes antígenos do HCV no "line immunoassay". A maioria dos doadores positivos tiveram história prévia de exposição parenteral. A combinação de ALT> 50 UI/l e positividade ao anti-HBc parece não ser eficaz como marcadores indiretos para a infecção pelo HCV, entretanto a dosagem do ALT e a detecção de anti-HCV são indicadas na triagem de doadores de sangue brasileiros.

Testes suplementares para melhorar a especificidade do anti-VHC por ELISA nos bancos de sangue não são oficialmente recomendados no Brasil. No intuito de avaliar a taxa de falso-positivos, 70 doadores com transaminases normais e anti-VHC por ELISA foram submetidos a imunoblot de 3ª geração no Hemocentro de Mato Grosso, que não dispõe da técnica da reação de cadeia de polimerase. O teste confirmou o anti-VHC em 44 (62,9%), sendo negativo em 22 (31,4%) e indeterminado em 4 (5,7%). Confirmação pelo imunoblot ajuda a identificar os testes ELISA que são falso-positivos, tranqüilizando o grande contingente de doadores nessa situação e separando os que necessitam de acompanhamento médico. Com esse objetivo, sugere-se que o imunoblot poderia ser útil nos bancos de sangue brasileiros que não contam com técnicas de Biologia Molecular.Supplemental tests using Immunoblot are recommended to improve specificity of anti-HCV by ELISA. In Brazil immunoblot is not officially recommended. Aiming to identify EIA false-positive rate 70 positive EIA anti-HCV blood donors were submitted to 3rd generation immunoblot at Hemocentro of Mato Grosso State where polymerase chain reaction tests are not performed. There were 44 (62.9%) immunoblot-positive, 22 (31.4%) negative and 4 (5.7%) indeterminate. Anti-HCV immunoblot can distinguish blood donors with false-positive ELISA from those who need medical assessment. Our data suggest that immunoblot could be useful in Brazilian blood banks where molecular biology tests are not available.

OBJETIVO: Determinar la prevalencia de hepatitis B, C, y VIH en una muestra ampliada de dos de las comunidades rurales en las que se registró la mayor prevalencia de anticuerpos anti-core del virus de la hepatitis (anti-HBc) en la Encuesta Nacional de Salud 2000 (ENSA 2000). MATERIAL Y MÉTODOS: Se realizó un estudio transversal en las comunidades de La Calera y Cuambio, dos poblaciones rurales adyacentes del municipio de Zirándaro, Guerrero, seleccionadas por mostrar muy alta prevalencia de anti-HBc en la ENSA 2000. Se determinó la prevalencia de marcadores séricos de hepatitis B y C, y VIH, así como factores sociodemográficos asociados entre los habitantes mayores de 10 años. RESULTADOS: Se confirmó una muy alta prevalencia de marcadores de hepatitis B, asociada con la edad, baja escolaridad y relaciones con trabajadoras sexuales en Estados Unidos, mientras que la prevalencia de hepatitis C fue baja y no se detectó ningún caso de VIH. CONCLUSIONES: Existen en México comunidades rurales con alta endemicidad de hepatitis B, en las cuales es conveniente profundizar la investigación de determinantes de la transmisión de este virus. Estas comunidades son identificadas con certeza por las encuestas nacionales de salud.OBJECTIVE: To perform a hepatitis B, C, and HIV survey in an enhanced sample from two rural communities with the highest anti-HBc prevalence found in ENSA 2000. MATERIALS AND METHODS: This was a cross-sectional study.We studied the communities of La Calera and Cuambio, two adjacent rural towns of the district of Zirándaro, Guerrero, targeted because of the high prevalence of anti-HBc shown in ENSA 2000.We assessed the prevalence of hepatitis B and C, and HIV serological markers and associated factors among inhabitants older than 10 years. RESULTS: A very high prevalence of hepatitis B markers associated with socioeconomic factors was confirmed, while hepatitis C prevalence was low and HIV absent in the two communities addressed. CONCLUSIONS: National serosurveys are an accurate tool for identifying communities with hepatitis B high endemicity where focused research and control measures are needed.

Seguimos ambulatorialmente, por no mínimo 180 dias, 111 receptores de transfusões, para avaliarmos a ocorrência de hepatites pós-transfusionais e os agentes etiológicos envolvidos com esta doença, na cidade de Campinas, Estado de São Paulo, Brasil. No final diagnosticamos esta hepatite em 18 (16,2%) receptores. Destes, tivemos 16 (89%) casos devido ao vírus da hepatite C, 1 (5,5%) causado pelo vírus da hepatite B e 1 (5,5%) caso restante, sem etiologia determinada, 15 meses após a transfusão. O período de incubação da hepatite por vírus C (HVC) foi de 71 dias, em média; e 23% dos indivíduos com esta hepatite permaneceram com aumento de AST/ALT por mais de 6 meses. Observou-se soroconversão tardia para o anti-HCV em 71,4% dos receptores, que ocorreu, em média, 135 dias após a transfusão. Uma dosagem de ALT e uma pesquisa do anti-HCV, aos 3 e 6 meses, após a transfusão, diagnosticariam, respectivamente, 71 e 93% dos casos que desenvolveram HVC pós-transfusionais.We have followed up 111 transfusion receptors in the ambulatory, for at least 180 days, in order to evaluate the occurence of post-transfusional hepatitis and the etiological agents involved in the disease in the city of Campinas, state of São Paulo, Brazil. At the end of the study we have diagnosed this hepatitis in 18 (16.2%) subjects. Out of these 18 subjects, 16 (89%) were caused by hepatitis C virus, 1 (5.5%) caused by hepatitis B virus and 1 (5.5%) with undetermined etiology, 15 months after transfusion. The average incubation period of HCV was 71 days and 23% of the HCV positive receptors remained with increased AST/ ALT for more than 6 months. Late serum conversion was observed for anti-HCV in 71.4% of the subjects, averaging 135 days after the transfusion. An ALT dosage and anti-HCV determination, 3 and 6 months after transfusion would diagnose, respectively, 71 and 93% of the cases which developed post-transfusional HCV.

Em 29833 doadores pesquisados encontramos prevalência de 1,52% para o HBsAg e de 11% para o anti-HBc. A co-positividade anti-HBc/anti-HBs em 2783 doadores HBsAg negativos/anti-HBc positivos foi de 81,9%. A prevalência para o HBsAg é baixa nos doadores de Campinas, enquanto o anti-HBc apresenta-se com prevalência elevada quando comparado a outros países. A pesquisa do anti-HCV, em doadores de sangue de Campinas, mostrou prevalência de 2,6% para este marcador, que é bem maior que as observadas nos EUA e Europa. Cerca de 36% dos doadores anti-HCV positivos são anti-HBc reagentes, permitindo inferir, que estas duas viroses acometem simultânea ou sequencialmente os doadores de sangue brasileiros.Among 29833 donors evaluated we have found a prevalence of 1.52% for HBsAg and 11% for anti-HBc. The co-positivity anti-HBc/anti-HBs in 2783 donors HBsAg negative/anti-HBc positive was 81.9%. The prevalence for HBsAg is low among Campinas donors, while anti-HBc presents high prevalence when compared to that of other countries. The anti-HCV detection in blood donors of Campinas has shown a positivity of 2.6% which is much higher than that of USA and Europe. About 36% of the anti-HCV positive donors are anti-HBc reagent, leading to the conclusion that these two "viruses" infect simultaneous or sequentially Brazilian blood donors.

Pesquisamos os anticorpos anti-HBc e anti-HCV em amostras de soros provenientes de 799 candidatos a doadores, que tiveram suas unidades de sangue ou derivados transfundidas a 111 receptores. O anti-HBc e o anti-HCV foram reagentes, em respectivamente 9 e 2,1% dos doadores testados. Observamos que entre os 111 receptores, 44 haviam recebido pelo menos uma unidade anti-HBc positiva e 67 haviam sido transfundidos somente com unidades anti-HBc negativas. Houve um risco 4,5 vezes maior de aquisição de hepatite por vírus C pelos receptores que receberam pelo menos uma unidade anti-HBc positiva Se a pesquisa do anti-HBc fosse realizada na triagem sorológica dos doadores de sangue, cerca de 56% dos casos de HVC nos receptores saiam evitados. A população de receptores que recebeu pelo menos uma unidade anti-HCV reagente, apresentou um risco 29 vezes maior de adquirir esta hepatite, quando comparada aos receptores transfundidos com todas as unidades anti-HCV negativas. A realização do teste para a pesquisa do anti-HCV na triagem dos doadores de sangue, preveniria 79% dos casos de HVC pós-transfusionais. Os candidatos a doadores brasileiros parecem ser acometidos simultânea ou sequencialmente, pelos vírus B e C das hepatites, pois, 44,4% dos doadores anti-HCV positivos, também foram anti-HBc positivos. A realização dos testes para as pesquisas dos anticorpos anti-HBc e anti-HCV, nas triagens hemoterápicas, está indicada para prevenir a transmissão de hepatites pós-transfusionais, em nosso meio.We have analysed anti-HBc and anti-HCV antibodies in serum samples from 799 donors which had their blood or derivates transfused to 111 recipients. Anti-HBc and anti-HCV were reactive in respectively 9 and 2.1% of the donors tested. We have observed that among the 111 recipients, 44 had received at least one positive anti-HBc unit and 67 had been transfused only with negative anti-HBc, units. The risk of developing hepatitis C virus was 4.5 times higher for the recipients who received at least one positive anti-HBc unit. If the test for anti-HBc had been made for the blood donors in the serological screening, about 56% of the HCV cases in the recipients could have been avoided. The population of recipients who received at least one reacting unit of anti-HCV, presented a risk 29 times higher of developing this hepatitis, as compared to the transfused recipients with all anti-HCV negative units. Testing blood from donors for anti-HCV would avoid 79% of the post-transfusional HCV cases. Brazilian candidates to blood donors seem to be carriers either simultaneously or sequentially to hepatitis virus B and C, since 44.4% of the positive anti-HCV were also positive for anti-HBc. Testing for anti-HBc and anti-HCV in blood screening must be indicated in order to prevent post-transfusional hepatitis transmission in our community.

Objective: The infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV) viruses pose a serious occupational risk for the healthcare workers especially those in emergency services, laboratories and surgery wards. Vaccination and establishment of the strict biosafety procedures are the main principles to prevent blood-borne infections in healthcare workers. Additionally, serological screening of the preoperative patients could decrease the risk for exposure. In this study, we aimed to determine the seroprevalence of HBsAg, anti-HCV, anti-HIV 1/2 in preoperative patients. Methods: Hospital automation records were evaluated retrospectively for 4.367 patients who were scheduled for surgery and scanned for anti-HIV 1/2, HBsAg and anti-HCV as preoperative procedures in the preparation period of operation between January 2012 and December 2012. Results: HBsAg positivity rate was found in 7.7% (n=336), anti-HCV positivity rate was found in 2.3% (n=101). A two (0.05%) of five patients were positive for anti-HIV 1/2 was found positive verification test and the other three samples were accepted as false positive test results. Conclusion: All healthcare workers must be trained about occupational diseases and vaccinated against Hepatitis B. Universal precautions must be strictly followed particularly in the operating room. In addition, all patients should be considered as potential carriers regarded as a carrier of the potential for infection. [ABSTRACT FROM AUTHOR]

Copyright of Viral Hepatitis Journal / Viral Hepatit Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Viral Hepatitis Journal / Viral Hepatit Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Viral Hepatitis Journal / Viral Hepatit Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Abstract: Background: Anti-HCV assays remain the first choice for screening HCV infection in most clinical laboratories. The Elecsys anti-HCV II assay has been recently launched and we aimed to evaluate its performance compared with other widely used methods. Methods: Four seroconversion panels, 861 consecutive sera under routine clinical conditions, 100 preselected sera with low positive anti-HCV results and 178 samples from patients infected with HIV were tested using Elecsys anti-HCV II, Architect anti-HCV and Vitros anti-HCV assays. Confirmatory testing was performed using RIBA and HCV RNA tests. Moreover, 203 samples with different HCV genotypes were assessed using Elecsys anti-HCV II. Results: Elecsys anti-HCV II detected seroconversion 7–14days earlier than the Architect and Vitros assays. Furthermore, it had 100% sensitivity and superior specificity in screening routine clinical samples, including those with low positive anti-HCV, and detected 97.6% (122/125) anti-HCV-positive samples from HIV-infected patients with HCV viremia. However, the anti-HCV levels in the genotype 3b samples were slightly underestimated. Conclusions: Elecsys anti-HCV II shortens the seroconversion window. It is suitable for screening HCV infection in clinical samples, including those from immunocompromised patients, due to the excellent sensitivity and specificity. Further investigation of the subtype inclusivity in a larger sample number might be warranted. [Copyright &y& Elsevier]

Highlights: [•] A new rapid kit, SD Bioline HCV had sufficient sensitivity and specificity for screening of HCV infection. [•] SD Bioline HCV had similar ability of early detection during window period compared to EIA. [•] SD Bioline HCV showed almost perfect agreement with RIBA. [ABSTRACT FROM AUTHOR]

Abstract: Background: hepatitis C infections are detected by anti-HCV screening tests. Reactive anti-HCV results give no information about the presence or absence of hepatitis C viruses, or of unspecific reactivity. To obtain information about the viral load, HCV RNA measurements, following a reactive anti-HCV result, are performed in well equipped and specialised laboratories. Anti-HCV immunoblots are the only means to exclude non specific reactivity. The measurement of HCV core antigen (HCV-Ag), as an alternative to HCV RNA, is discussed, as it can be analysed on the same instrument as anti-HCV. Objectives: The detection limit of HCV-Ag is crucial to use it in lieu of HCV RNA, in regard of the different genotypes. A renewed algorithm is proposed to exclude unspecific reactivity of anti-HCV. Study designs: Samples were tested on Architect i2000SR (Abbott) for anti-HCV and HCV-Ag. HCV RNA measurements were obtained by Cobas Ampliprep/Taqman (Roche) or m2000rt® (Abbott). Results and Conclusions: Comparison between HCV-Ag and HCV RNA from 126 samples of 101 patients with chronic hepatitis C gave linear regression R 2 0.89, slope 0.885 and intercept −2.258, which were independent of the genotypes. The detection limit of HCV-Ag was between 2.4 and 4.5Log10 IU/mL. A renewed algorithm for confirmation of reactive anti-HCV results is proposed: active or resolved hepatitis C infections or false reactivity can be differentiated by sequenced reflex testing due to HCV-Ag, anti-HCV immunoblot and HCV RNA. [Copyright &y& Elsevier]

Background & objectives: Transfusion of blood and blood products although considered as a life saving treatment modality, but may lead to certain infectious and non-infectious complications in the recipients. The purpose of this analysis was to monitor the seroprevalence of anti-HCV antibody in the blood donor population in a hospital based blood bank in north India, to evaluate the trends over the years (2001-2011). Methods: Relevant information of all the blood donors who donated whole blood at the department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi from the January 1, 2001 to December 31, 2011 was retrieved from the departmental records. The number of donors who were found reactive for anti-HCV anatibodies was calculated. Results: Of the 2,06,022 blood donors, 1,93,661 were males and 12,361 were females. The percentage of whole blood donors found seroreactive for anti-HCV antibodies was 0.39 per cent (n=795). The seroprevalence of anti-HCV in male blood donors was 0.38 per cent (n=750) and the respective seroprevalence in female blood donors was 0.36 per cent (n=45). No significant change in the trend of HCV seroprevalence was observed over the period under consideration. Maximum seroprevalence of anti-HCV was observed in the age group of 18 to 30 yr (0.41%) and the minimum in the age group of 51 to 60 yr (0.26%). Interpretation & conclusion: HCV seroprevalence in our study was 0.39 per cent and a decreasing trend with age was observed. No significant change in the trend of anti-HCV seroprevalence was seen over a decade. Since, no vaccine is presently available for immunization against HCV infection, transfusion transmitted HCV infection remains a potential threat to the safety of the blood supply. [ABSTRACT FROM AUTHOR]

Objective: Hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are viruses that can be transmitted to the health care workers by infected body fluids and from mother to the baby before, during or after delivery. In the present study, we aimed to investigate the frequency of hepatitis B surface antigens (HBsAg), hepatitis C antibodies (anti-HCV), and HIV antibodies (anti-HIV) in pregnant women and/or patients with gynecologic diseases that admit to a university hospital in Bolu. Methods: HBsAg, anti-HCV, and anti-HIV results of the pregnant women and/or patients with gynecologic diseases that admitted to the obstetrics and gynecology clinics between January 2006 and June 2012 were retrospectively investigated. All markers were tested in the microbiology laboratory of our hospital by using macro ELISA method (Axsyme and Architect i2000SR systems, Abbott Diagnostics, Chicago, IL, USA). Results: The frequency of HBsAg, anti-HCV, and anti- HIV positivity were 1.8%, 0.5%, and 0% in pregnant women and 1.9%, 1.1%, and 0% in patients with gynecologic diseases, respectively. Conclusion: The frequencies detected in our hospital are at low levels as seen in developed countries. Since there is no effective method of prevention especially from HCV, awareness of this serologic result before high risk procedures will enable the doctors and the health care workers to take extensive measures to prevent the transmission of the disease. [ABSTRACT FROM AUTHOR]

Abstract: A new compound library that contained 20 hinged benzimidazole–coumarin hybrids and their β-d-ribofuranosides was established. The anti-hepatitis C virus (HCV) activity of all novel coumarin derivatives, which were obtained by use of organic synthetic methods, was tested. Two of these hybrids exhibited appealing EC50 values of as low as 3.0 and 5.5 μM. The best selectivity index was 14. The incorporation of a d-ribofuranose into the hinged hybrids provided the corresponding nucleosides with the β configuration, one of which inhibited HCV replication with an EC50 value of 20 μM. Additionally, the structure–activity relationship is elucidated on the basis of the functional groups that were attached to the nuclei of benzimidazole, coumarin, and ribofuranose of the hybrids. [Copyright &y& Elsevier]

Abstract: Recently, peptide drugs have evolved into mainstream therapeutics, representing a significant portion of the pharmaceutical market. However, their bioavailability remains to be improved compared with that of chemical drugs. Here, we screened and identified a new peptide, Ctry2459, from a scorpion venom peptide library that was proven to inhibit hepatitis C virus (HCV) infection via inactivating infectious viral particles. However, Ctry2459 cannot suppress established infection of HCV because of the poor cellular uptake and restriction of endosomes. Based on the molecular template of the Ctry2459 peptide, we designed two histidine-rich peptides (Ctry2459-H2 and Ctry2459-H3) with significantly enhanced cellular uptake and improved intracellular distribution. Moreover, the two mutated peptides, as well as the wild-type peptide Ctry2459, exhibited virucidal activities against HCV. In distinct contrast to the Ctry2459 peptide, the mutated peptides significantly suppressed the established HCV infection at the cellular level but demonstrated lower cytotoxic and hemolytic activities. Our work presents an effective design strategy for optimizing natural antiviral peptides and opens a new avenue for enhancing the bioavailability of peptide drugs. [Copyright &y& Elsevier]

Copyright of Viral Hepatitis Journal / Viral Hepatit Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Viral Hepatitis Journal / Viral Hepatit Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Hepatitis C virus (HCV) infection is a global health threat and current therapies warrant the need for novel HCV therapies. Several synthetic analogs targeting HCV serine protease and RNA-dependent RNA polymerase have entered clinical development. To investigate the novel HCV NS5B RdRp polymerase inhibitor, screening of a designed data set consisting of benzimidazole analogs by the FlexX docking approach was performed. Binding interactions at the active sites (PDB ID: 2DXS) were evaluated leading to the rationalization of further synthesis and evaluation procedures. [ABSTRACT FROM AUTHOR]

Rapid tests (RT) have been widely used for screening of hepatitis C virus (HCV) in general population, but its performance in hemodialysis (HD) patients and mainly in kidney-transplant recipients (RTx) is less known. The aim of this study was to evaluate the accuracy of RT for detection of anti-HCV in HD and RTx patients. Patients were prospectively included subdivided in four groups according to the positivity for anti-HCV detected by conventional serology: (1) HD patients anti-HCV +, (2) HD patients anti-HCV -, (3) RTx patients anti-HCV +, and (4) RTx patients anti-HCV -. All patients were retested for HCV using the commercial kit Alere HCV ® Bioeasy Rapid Test (Bioeasy Diagnóstica LTDA-Minas Gerais, Brazil) in capillary whole blood samples. During the period of study were included 46 HD patients anti-HCV+, 62 HD patients anti-HCV -, 53 RTx patients anti-HCV + and 56 RTx patients anti-HCV -. In patients on HD, the RT showed sensitivity (S), specificity (SP), positive predictive value (PPV), negative predictive value (NPV), and accuracy of 100%. In RTx patients, S of 96%, SP of 100%, PPV of 100% and NPV of 97% were found (accuracy of 98%). In conclusion, in patients on HD there was 100% agreement between RT and the conventional immunoassay. In the RTx group, although the agreement was not 100%, the RT performed very well when compared to conventional serology. This study demonstrates that the RT can be an alternative to conventional serology in HCV screening of patients on HD and RTx.

Introduction: Several viral infections cause life-threatening consequences in humans, making them the most serious public health concerns. Despite the fact that several antiviral medicines are available on the market, there is no full treatment for many important viral infections. To date, antiviral medicines have significantly reduced the spread of epidemics, but their continued use has resulted in the creation of drug-resistant variants throughout time. As a result, the development of new, safe, and efficient antiviral drugs is critical., Areas Covered: This review covered reports in the patent literature in the period 2014 to the first quarter of 2021 on the antiviral activities of thiazole derivatives. These molecules were reported to inhibit a wide range of viruses including influenza viruses, coronaviruses, herpes viruses, hepatitis B and C, bovine viral diarrhea virus, chikungunya virus and human immunodeficiency viruses., Expert Opinion: The most bioactive molecules can be used as lead structures for the development of new thiazole compounds with potent and selective antiviral activity. In addition, more efforts are needed to better understand the host-virus interactions for the discovery and development of new therapeutic agents and creative treatment strategies that are supposed to improve rates of clinical cure of the serious viruses.

Abstract: A series of 2′,3′-dideoxy-2′,2′-difluoro-4′-azanucleosides of both pyrimidine and purine nucleobases were synthesized in an efficient manner starting from commercially available L-pyroglutamic acid via glycosylation of difluorinated pyrrolidine derivative 15. Several 4′-azanucleosides were prepared as a separable mixture of α- and β-anomers. The 6-chloropurine analogue was obtained as a mixture of N7 and N9 regioisomers and their structures were identified based on NOESY and HMBC spectral data. Among the 4′-azanucleosides tested as HIV-1 inhibitors in primary human lymphocytes, four compounds showed modest activity and the 5-fluorouracil analogue (18d) was found to be the most active compound (EC50 =36.9μM) in this series. None of the compounds synthesized in this study demonstrated anti-HCV activity. [Copyright &y& Elsevier]

Abstract: Toxic and essential trace metals, oxidative stress, and inflammatory status were evaluated in anti-hepatitis C virus (HCV) antibody-positive subjects. Blood biochemical parameters were determined in anti-HCV antibody-positive (n =17) and -negative controls (n =46). Compared with controls, anti-HCV antibody-positive individuals had significantly lower concentrations of plasma zinc (Zn); higher copper (Cu), iron (Fe), lead (Pb), cadmium (Cd), and aluminum (Al); and lower activities of erythrocyte antioxidant enzymes glutathione peroxidase and catalase, and elevated superoxide dismutase. Significantly increased lipid peroxidation malondialdehyde (MDA), and inflammatory markers such as alanine aminotransferase (ALT), high sensitivity C-reactive protein (hs-CRP), ferritin, and Cu/Zn ratios, as well as decreased albumin and high density lipoprotein (HDL) concentrations were observed. We have found significant interactions between toxic (e.g., Pb, Cd, and Al) and essential metals (e.g., Zn, Cu, Fe), which correlated with MDA. In conclusion, anti-HCV antibody-positive subjects had abnormal distributions of trace metals that may aggravate oxidative stress and inflammation, and exacerbate hepatic damage. [Copyright &y& Elsevier]

Objective: Hepatitis C virus (HCV) infection is a global health problem. According to WHO data, approximately four million people are infected with HCV each year and 350 million people die due to liver diseases associated with this virus. HCV is a RNA virus belonging to Flaviviridae family and a major cause of acute and chronic hepatitis; mainly caused by transfussion of the infected blood. Organ transplantation, intravenous drug use, sexual intercourse, and perinatal transmission are additional causes ofinfection. The aim of this study was to determine the HCV RNA in serum samples with low levels of anti-HCV antibodies, received at Tepecik Education and Research Hospital Infectious Diseases and Clinical Microbiology Laboratory. Method: Serum samples received at Tepecik Education and Research Hospital Infectious Diseases and Clinical Microbiology Laboratory between September 1, 2009 and July 10, 2010 were studied by chemiluminescent assay (Architect i1000, Abbott, USA) for anti-HCV and COBAS AmpliPrep / COBAS AMPLICOR HCV Test (Roche diagnositics, Switzerland) for HCV RNA. Results: A total of 4,741 serum samples were studied, and 204 of them were anti- HCV positive, 20 of which with low antibody levels (sample/cutoff [S/CO]) 1-2). HCV RNA was not detected in any of the samples with low positivity levels. Conclusion: Serum samples with low anti-HCV positivity should be studied once again by enzyme immuno assay (EIA) and later by HCV RNA test for confirmation. The use of both EIA and molecular methods would help in the cofirmation of positive assay results and early diagnosis. Currently, laboratories use either "second-" or "third-generation" EIA tests that detect antibodies against different regions of the HCV genome. The sensitivity of the third generation assays are more than 95% and there are less false positive results. However, they could show false positivity when tested with anti-HCV chemiluminescent assay. Therefore, it is important to confirm the results by HCV RNA assay, so that unnecessary treatments could be avoided. [ABSTRACT FROM AUTHOR]

Objective. To perform a hepatitis B, C, and HIV survey in an enhanced sample from two rural communities with the highest anti-HBc prevalence found in ENSA 2000. Materials and Methods. This was a cross-sectional study. We studied the communities of La Calera and Cuambio, two adjacent rural towns of the district of Zirándaro, Guerrero, targeted because of the high prevalence of anti-HBc shown in ENSA 2000. We assessed the prevalence of hepatitis B and C, and HIV serological markers and associated factors among inhabitants older than 10 years. Results. A very high prevalence of hepatitis B markers associated with socioeconomic factors was confirmed, while hepatitis C prevalence was low and HIV absent in the two communities addressed. Conclusions. National serosurveys are an accurate tool for identifying communities with hepatitis B high endemicity where focused research and control measures are needed. [ABSTRACT FROM AUTHOR]

In pursuit of more active thioureas as anti-HCV agent, QSAR studies were performed on a series of thioureas to explore the various physico-chemical parameters responsible for their activity against HCV-infected AVa 5 cell. Physico-chemical parameters were calculated using WIN CAChe 6.1. Stepwise multiple linear regression analysis was performed to derive QSAR models which were further evaluated for statistical significance and predictive power by internal and external validation. The selected best QSAR model was having correlation coefficient ( R) = 0.902 and cross-validated squared correlation coefficient ( Q) = 0.734. The developed significant QSAR model indicates that hydrophobicity, dielectric energy, valence connectivity index (order 1), and ionization potential of whole molecule play an important role in anti-HCV activity of thioureas. The hydrophobicity of thioureas was found to have parabolic relation with its anti-HCV activity. The optimum log P value for these anti-HCV compounds was found to be 4.988. Graphical abstract: In this study, the role of hydrophobicity on anti-HCV activity of thiourea derivatives is discussed. It has been found that the optimum log P value for these anti-HCV compounds was 4.988.[Figure not available: see fulltext.] [ABSTRACT FROM AUTHOR]

Background: HBsAg and anti-hepatitis C virus (anti-HCV) are stable markers and widely used. The seroconversion and seroclearance of HBsAg and anti-HCV are important for disease control and prognosis of diseases. Aims: To investigate acquirement and disappearance of HBsAg and anti-HCV in an endemic area. Methods: Seven years after a community screening, 1002 of 2909 residents of Tzukuan Township were recruited. HBsAg, anti-HCV and alanine transaminase (ALT) were checked in all who participated and hepatitis B virus (HBV) DNA, anti-HBs, anti-HBc, HCV RNA, anti-HDV andupper abdominal ultrasonography were studied in different groups. Results: Therewere 461 male and 541 female residents with a mean age of 66.7% 8.6 years. No new HBsAg carrier was noted and the HBsAg clearance rate was 1.58% per year. One of the 17 cases with HBsAg clearance had positive HBV DNA, three had ALT elevation, two had cirrhosis and seven had anti-HBs seroconversion. Quantitative of HBsAg and HBV DNA wereconcordant and 78.1% subjects had low levels of titration. Anti-HBc alone contributed to 32.1% and was prominent in old age and the anti-HCV positive group. The anti-HCV seroconversion rate was only 0.74% per year and household transmission was the only risk factor. Only 37.5% of cases with anti-HCV seroconversion had HCV viraemia and the anti-HCV seroreversion rate was 0.63% per year. The anti-HDV seroconversion rate was 0.72% per year and no subject showed anti-HDV clearance. Conclusions: Much higher rates of HBsAg seroclearance, anti-HCV seroreversion and anti-HBc alone were noted in this endemic area and no subject showed anti-HDV clearance. [ABSTRACT FROM AUTHOR]

Abstract: An efficient method was developed for the synthesis of 6-exocyclic methylene carbocyclic intermediate 4. The Simmons–Smith cyclopropanation protocol was applied on the 6-exocyclic methylene of intermediate 4 and demonstrated its utility for the synthesis of novel class of a spiro-carbocyclic nucleoside analog 8. The titled compound 8 demonstrated a significant antiviral activity against HCV with EC50 values of 0.273 and 0.368μM in genotypes 1A and 1B, respectively. [Copyright &y& Elsevier]

Background: Hepatitis C virus is a major burden on public health worldwide. This study was conducted to evaluate the frequency and various risk factors for hepatitis C virus among pregnant women in our set-up. Material & Methods: This cross-sectional study was conducted on pregnant women in Gynaecology & Obstetrics Department, Kuwait Teaching Hospital, Peshawar, from January 2007 to January 2009. After detailed history and examination, 5 ml blood was taken. Rapid Immuno-chromatographic Technique for qualitative detection of antibodies for hepatitis C was the screening technique used. Those found positive were confirmed by ELISA. The women were also evaluated for the presence of risk factors for Hepatitis C virus infection. Pre-structured proforma was used to collect and record data. Results were analyzed on SPSS version 16. Results: During the study period 2050 pregnant women were tested for anti-HCV. Out of these, 103(5%) were found positive for anti-HCV. Regarding risk factors; history of previous delivery, abortions, injections, blood transfusion, surgery, dental extraction and tattooing were associated with HCV positive status. Sixty-four (62%) anti-HCV positive women did not have any identifiable risk factor. Conclusion: Hepatitis C is a common infection in pregnant women. Risk factors include use of contaminated syringes, contaminated surgical instruments and blood products. [ABSTRACT FROM AUTHOR]

Background: Hepatitis C is prevalent worldwide. In Pakistan HCV infection has prevalence of about 4-6%. This study was conducted to identify the risk factors associated with positive hepatitis C status in a tertiary care setting. Material & Methods: This was hospital-based descriptive study, carried out in medical wards of Lady Reading Hospital, Peshawar, from June 2008 to November 2010. It included 542 anti-HCV positive patients of more than 12 years age and both sexes. Patients were selected by convenient sampling technique. Various indications for HCV testing and the risk factors for its acquisition were recorded on a pre-designed Performa. Results: Out of 542 patients, 228(42.07%) were males and 314(57.93%) females. Age ranged 14 to 90 years with mean 37.11+12.69. Re-use of syringes and therapeutic injections were reported in 433(79.88%), needle stick injuries 44(8.11%), blood transfusions 68(12.54%), dental procedures 243(44.83%), tattooing 10(1.84%), previous surgery 144(26.56%) and road traffic accidents in 16(2.95%) patients. Indications for anti-HCV testing included dilatation &/curettage in 37(11.78%), evacuation &/curettage in 41(13.05%), and antenatal checkup in 37(11.78%) female patients. Anti-HCV antibodies were detected pre-operatively in 63(11.62%), pre-endoscopy 2(0.36%), pre-vaccination against hepatitis B 14(2.58%), while donating blood in 18(3.32%), and as part of pre-employment or pre-insurance examination in 91(16.78%) patients. Conclusion: Hepatitis C is more common in patients with unnecessary use of injections, re-use of syringes, dental procedures and unscreened blood transfusions. In most of the patients, more than one risk factor can be found. [ABSTRACT FROM AUTHOR]

Quantitative structure-activity relationship (QSAR) studies were performed on a series of thioureas to explore the physico-chemical parameters responsible for their activity against the hepatitis C virus (HCV)-infected AVa5 cell. The physico-chemical parameters were calculated using WIN CAChe 6.1. Multiple linear regression analysis, after the variables selection by factor analysis, was performed to derive QSAR models which were further evaluated for their statistical significance and predictive power by internal and external validation. The developed QSAR model had the correlation coefficient (R) = 0.928 and cross-validated squared correlation coefficient (Q2) = 0.751. The selected significant QSAR model indicates that hydrophobicity, dielectric energy, valence connectivity index (order 1), conformational minimum energy and highest occupied molecular orbital of the whole molecule play an important role in the anti-HCV activity of thioureas. [ABSTRACT FROM AUTHOR]

Background and Aim: This study attempted to clarify accuracy of acute hepatitis C (AHC) and its clinical characteristics. Methods: We reviewed 632 reported cases from national surveillance data of the Taiwan Center for Disease Control between 1995 and 2004, and reclassified diagnoses. A definite case was defined as alanine aminotransferase (ALT) > 10 × the upper limit of normal (ULN) with seroconversion of anti-hepatitis C virus antibody (anti-HCV). A probable case was defined as (i) seroconversion of anti-HCV and/or elevated ALT levels; or (ii) anti-HCV(+) but titers increased (from < 40 S/CO to ≥ 40 S/CO) and ALT > 10 × the ULN. A suspected case was defined as initial anti-HCV(+) and ALT level > 10 × the ULN and/or jaundice. Excluded cases were defined as ALT levels less than 10 × ULN with initial positive anti-HCV Ab. Results: A total of 310 (49%) cases were confirmed as AHC; these included 95 (15%) definite and 215 (34%) probable cases. Higher incidence rates and accuracy of AHC were demonstrated in the southern area significantly if compared with northern, eastern and central areas, respectively (all P < 0.05). On comparison between blood centers and hospitals, more AHC cases were found in Southern Taiwan than in other areas (157/73 vs 24/40, P < 0.001), younger mean age (33.3 ± 11.1 vs 49.3 ± 16.4, P < 0.001), lower ALT levels (263.1 ± 200.9 vs 1264.2 ± 706.8, P < 0.001) and male predominance (191/39 vs 46/18, P = 0.046). Conclusions: This study showed our reporting system over-estimated the AHC diagnosis, which is also a common issue worldwide. Greater efforts are needed to establish appropriate reporting systems, as well as more supplemental methods to distinguish between prevalent and incident cases. [ABSTRACT FROM AUTHOR]

Hepatitis C virus (HCV) infection is increasingly recognized as a major health care problem, and is found frequently in Pakistani settings. In this article we reviewed published and unpublished data related to the seroepidemiology of HCV infection in Pakistan. For this article, data from 132 published studies and three unpublished data sets published/ presented between the period 1992-2008 were utilized. Data of 1,183,329 individuals were gathered. Blood donors (982,481) and the general population (178,322) constituted the majority of these subjects. The frequency of HCV infection in blood donors and in the general population was 3.0 % (95% CI: 3.0- 3.1) and 4.7 (95% CI: 4.6 -4.8), respectively. The frequency among 6,148 pregnant females was 7.3% (95% CI = 6.7 - 8.0). The frequency in healthy children ranged from 0.4 to 4.1% (95% CI = 1.4 - 2.3). Pakistani HCV serofrequency figures are significantly higher (P < 0.0001) compared to those of the corresponding populations in surrounding countries like India, Nepal, Myanmar, Iran and Afghanistan. [ABSTRACT FROM AUTHOR]

Abstract: Three series of novel pyrazole derivatives 2b–d, 4a–d and 6a–d were synthesized via two step procedure that utilizes hydrazonoyl chlorides 1a–d and enaminones 3a–d and 5a–d, respectively as starting materials. The structures of all the newly synthesized products have been established on the basis of analytical and spectral data. Moreover, some of the products 2–6 were tested against HCV and Subacute Sclerosing Panencephalitis (SSPE). In addition, compounds 2–6 were also tested for the inhibition of peroxynitrite-induced tyrosine nitration and antioxidant activity. The tested compounds are highly effective at very low concentration as anti-HCV, SSPE antioxidant and anticancer in the following ascending order 2d, 4c, 6b, 3b, 6c, 4d, 2b, 2c, 2a, 6a, 5b, 5a, 3a, 4b and 5c. It is worth to mention that all tested compounds are more potent than the reference standards used for comparing activity. All the measurements revealed that the mechanism of action of the anti cancer activities of all the tested compounds is topoisomerase I inhibitor. [Copyright &y& Elsevier]

Background & Aims: Hepatitis C virus (HCV) infection has been shown to be associated with a low platelet count. This study aimed to elucidate the association between virologic status and platelet count in individuals with HCV infection. Methods: A large-scale survey, enrolling 11,239 residents, was conducted in the Kaohsiung area of Taiwan. Serum HCV RNA and non-invasive markers of fibrosis (FibroTest) were tested for antibody to HCV (anti-HCV)-positive subjects. The platelet counts of age- and sex-matched, biopsy-proven, hospital-based patients and community-based patients with minimal fibrosis were compared. Results: Anti-HCV was positive in 703 (6.2%) subjects and was significantly associated with older age, female sex, abnormal alanine aminotransferase (ALT) value and low platelet count (<150,000/μl). The independent factors significantly associated with low platelet count were abnormal ALT value (odds ratio [OR]: 3.70, 95% confidence intervals [CI]: 2.18–6.28) and positive HCV RNA (OR: 2.00, 95% CI: 1.01–3.97). After adjustment for the fibrosis, HCV RNA remained significantly associated with platelet counts. Conclusions: Our results evaluating the association between platelet count and HCV viremia and taking the influences of fibrosis into consideration implicate that platelets may be affected directly by HCV. [Copyright &y& Elsevier]

Background and Aims: Patients undergoing hemodialysis are at risk of infection with both hepatitis B virus (HBV) and hepatitis C virus (HCV). Occult HBV infection is usually associated with low levels of HBV and is frequently detected in HCV-infected patients. The aims of the present study were to compare the prevalence of occult HBV infection among anti-HCV-positive and anti-HCV-negative patients undergoing hemodialysis, and characterize the molecular patterns of HBV isolates from patients with occult infection. Methods: Serum samples from 100 patients negative for hepatitis B surface antigen undergoing hemodialysis, half of whom were positive for anti-HCV antibodies, were tested for the presence of HBV-DNA using semi-nested polymerase chain reaction (PCR). PCR products of the S gene were directly sequenced. Results: HBV-DNA was detected in 15 samples. There were no significant differences in HCV status, sex, age, time of dialysis, alanine aminotransferase levels or HBV serological markers between patients with or without occult HBV infection, with the exception of antibody to hepatitis B core antigen (anti-HBc)-only serological marker ( P = 0.003). All six HBV isolates that could be sequenced were of genotype A/subgenotype A1. Four of these six HBV isolates contained mutations associated with lamivudine resistance in the DNA polymerase (two with L180M/M204V and two with rt173V/180M/204V) and a specific substitution (Y100C) in the HBV small surface protein. Conclusions: HBV isolates with the identified substitutions have the potential to spread silently by nosocomial transmission within the hemodialysis unit. These results have potential implications for the management of patients with occult HBV infection undergoing hemodialysis. [ABSTRACT FROM AUTHOR]

Objective: In this study, we aimed to determine the seropositivity of HBsAg, anti-HCV, anti-HIV 1+2 among individuals admitted to Suleyman Demirel University Research and Education Hospital. Material and Methods: HBs Ag (16865 tests), anti-HCV (16098 tests) and anti-HIV 1+2 (13758 tests) results were retrospectively evaluated among individuals admitted to our hospital between January 2013 and December 2013. HBs Ag, anti-HCV, anti-HIV 1+2 tests in the serum of patients were measured with chemiluminescence method (Vıtros, Johnson&Johnson, USA). Results: The seroprevalence of HBs Ag, anti-HCV and anti-HIV 1+2 were found as 5.9 %, 2.3 % and 0.01 %, respectively. Conclusion: Consequently, healthcare workers must be trained about occupational diseases and should be vaccinated against Hepatitis B. In order to prevent the infection risk, should be take measure, against potentially infectious agents. [ABSTRACT FROM AUTHOR]

Abstract: The EIAgen HCV test (Adaltis Inc., Montreal, Canada) is an enzyme immunoassay (EIA) for the detection of anti-hepatitis C virus (HCV) antibodies. This study compared the performance of this test side-by-side with the current Ortho HCV 3.0 Anti-HCV assay (Ortho-Clinical Diagnostics Inc., Johnson & Johnson Company, Raritan, NY, USA). Among 2559 specimens examined, 178 were true positives, 2376 were true negatives and 5 were indeterminate. The sensitivity of the EIAgen HCV test was 100%, versus 98.3% for the Ortho HCV test, while their respective specificities were 98.1% and 98.2%. The EIAgen HCV test gave a positive predictive value of 79.8% and a negative predictive value of 100%. Overall, the concordance of this test with the Ortho HCV test was 98.2%. Specimens from potentially interfering substances, such as sera from pregnant women, sera from patients with acute non-C hepatitis, autoimmune diseases, lipidemia, or from patients undergoing hemolysis, showed no interference with either EIA. An EIAgen HCV test signal-to-cut-off ratio of >5.9 would be highly predictive of a true-positive finding in these specimens. The EIAgen HCV test is well suited for screening blood and blood products in antibodies to HCV. [Copyright &y& Elsevier]

Abstract: 2-Dimethylaminomethylene-1-benzosuberone 1 was coupled with diazotized aniline derivatives to afford a series of the hitherto unreported 2-arylazo-1-benzosuberones 3a–i. The tautomeric structure and the effect of substituents on the tautomeric form (s) of the products 3a–i were discussed. Similar coupling of the enaminone 1 with diazonium salts of heterocyclic amines gave the respective fused azolotriazino-benzosuberones. Some of the newly synthesized compounds showed potent antimicrobial, anti-HCV, antioxidant, antitumor (as topoisomerase I inhibitors), and antimicrobial activities. [Copyright &y& Elsevier]

Objectives: Exposure to blood borne pathogens is the most serious occupational health risk faced by healthcare workers. The aim of this study was to evaluate the preoperative seroprevalences of HBsAg, anti-HCV and anti-HIV. Materials and methods: In this study we evaluated the seroprevalence of HBsAg, anti-HCV and anti-HIV in 486 preoperative patients who admitted to Dicle University Medical Faculty General Surgery Clinic for elective surgical procedures between January 2007 and July 2007; retrospectively. The results were compared with those of 14354 blood donations during the same period as control group. Results: The seroprevalence of HBsAg and anti-HCV were; %6.6 and %1.6 subsequently in preoperative patients. HBsAg and anti-HCV seropositivity rates were lower in the control group. Thus, the positively rates of HBsAg and anti-HCV for preoperative patients should be assessed higher than the data obtained from the blood bank. Anti-HIV seropositivity was not detected in both patient and control group. Conclusion: All healthcare workers must be trained about occupational diseases and vaccinated against hepatitis B. Establishment of universal precautions is necessary and these precautions must be strictly followed particularly in the operating room. In addition all patients should be considered as potential carriers. [ABSTRACT FROM AUTHOR]